메뉴 건너뛰기




Volumn 18, Issue 1, 2016, Pages 10-16

Use of varenicline in smokeless tobacco cessation: A systematic review and meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE; NICOTINIC AGENT;

EID: 84954529787     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv010     Document Type: Review
Times cited : (6)

References (49)
  • 1
    • 34848885468 scopus 로고    scopus 로고
    • A change in the air: smoking bans gain momentum worldwide
    • Schmidt CW. A change in the air: smoking bans gain momentum worldwide. Environ Health Perspect. 2007;115:A412-A415.
    • (2007) Environ Health Perspect , vol.115 , pp. A412-A415
    • Schmidt, C.W.1
  • 2
    • 84954550684 scopus 로고    scopus 로고
    • 130521smokelesstobaccoreport.pdf. Accessed June 6, 2014
    • 130521smokelesstobaccoreport.pdf. www.ftc.gov/sites/default/files/documents/reports/federal-trade-commission-smokeless-tobacco-report-2011/130521smokelesstobaccoreport.pdf. Accessed June 6, 2014.
  • 3
    • 61449129668 scopus 로고    scopus 로고
    • Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking?
    • Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? Int J Environ Res Public Health. 2009;6:10-24. doi:10.3390/ijerph6010010.
    • (2009) Int J Environ Res Public Health , vol.6 , pp. 10-24
    • Tomar, S.L.1    Fox, B.J.2    Severson, H.H.3
  • 4
    • 33750445307 scopus 로고    scopus 로고
    • Public health implications of smokeless tobacco use as a harm reduction strategy
    • Savitz DA, Meyer RE, Tanzer JM, Mirvish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health. 2006;96:1934-1939. doi:10.2105/AJPH.2005.075499.
    • (2006) Am J Public Health , vol.96 , pp. 1934-1939
    • Savitz, D.A.1    Meyer, R.E.2    Tanzer, J.M.3    Mirvish, S.S.4    Lewin, F.5
  • 5
    • 34547565089 scopus 로고    scopus 로고
    • Should the health community promote smokeless tobacco (snus) as a harm reduction measure?
    • Gartner CE, Hall WD, Chapman S, Freeman B. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med. 2007;4:e185. doi:10.1371/journal.pmed.0040185.
    • (2007) PLoS Med , vol.4
    • Gartner, C.E.1    Hall, W.D.2    Chapman, S.3    Freeman, B.4
  • 6
    • 84901780853 scopus 로고    scopus 로고
    • Smokeless tobacco use among working adults-United States, 2005 and 2010
    • Mazurek JM, Syamlal G, King BA, Castellan RM; Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC. Smokeless tobacco use among working adults-United States, 2005 and 2010. MMWR Morb Mortal Wkly Rep. 2014;63:477-482.
    • (2014) MMWR Morb Mortal Wkly Rep , vol.63 , pp. 477-482
    • Mazurek, J.M.1    Syamlal, G.2    King, B.A.3    Castellan, R.M.4
  • 7
    • 79955586900 scopus 로고    scopus 로고
    • Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines
    • Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control. 2011;20:e2. doi:10.1136/tc.2010.037465.
    • (2011) Tob Control , vol.20
    • Stanfill, S.B.1    Connolly, G.N.2    Zhang, L.3
  • 9
    • 17044407160 scopus 로고    scopus 로고
    • Smokeless tobacco use and risk of cancer of the pancreas and other organs
    • Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer. 2005;114:992-995. doi:10.1002/ijc.20811.
    • (2005) Int J Cancer , vol.114 , pp. 992-995
    • Boffetta, P.1    Aagnes, B.2    Weiderpass, E.3    Andersen, A.4
  • 10
    • 69949091626 scopus 로고    scopus 로고
    • Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis
    • Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. 2009;339:b3060.
    • (2009) BMJ , vol.339
    • Boffetta, P.1    Straif, K.2
  • 11
    • 84954476053 scopus 로고    scopus 로고
    • Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings-nsduhresults2011.pdf. Accessed June 4, 2014
    • Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings-nsduhresults2011.pdf. www.samhsa.gov/data/nsduh/2k11results/nsduhresults2011.pdf. Accessed June 4, 2014.
  • 12
    • 84891791619 scopus 로고    scopus 로고
    • Pharmacological interventions for smoking cessation: an overview and network meta-analysis
    • Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329. doi:10.1002/14651858. CD009329.pub2.
    • (2013) Cochrane Database Syst Rev , vol.5
    • Cahill, K.1    Stevens, S.2    Perera, R.3    Lancaster, T.4
  • 14
    • 83455186148 scopus 로고    scopus 로고
    • Pharmacological interventions for the treatment of smokeless tobacco use
    • Ebbert JO, Fagerström K-O. Pharmacological interventions for the treatment of smokeless tobacco use. CNS Drugs. 2012;26:1-10. doi:10.2165/11598450-000000000-00000.
    • (2012) CNS Drugs , vol.26 , pp. 1-10
    • Ebbert, J.O.1    Fagerström, K.-O.2
  • 17
    • 77957747183 scopus 로고    scopus 로고
    • A pilot study to assess smokeless tobacco use reduction with varenicline
    • Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res. 2010;12:1037-1040. doi:10.1093/ntr/ntq134.
    • (2010) Nicotine Tob Res , vol.12 , pp. 1037-1040
    • Ebbert, J.O.1    Croghan, I.T.2    North, F.3    Schroeder, D.R.4
  • 19
    • 78650003597 scopus 로고    scopus 로고
    • Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
    • Fagerström K-O, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010;341:c6549.
    • (2010) BMJ , vol.341
    • Fagerström, K.-O.1    Gilljam, H.2    Metcalfe, M.3    Tonstad, S.4    Messig, M.5
  • 20
    • 80052770427 scopus 로고    scopus 로고
    • A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States
    • Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. Nicotine Tob Res. 2011;13:820-826. doi:10.1093/ntr/ntr078.
    • (2011) Nicotine Tob Res , vol.13 , pp. 820-826
    • Ebbert, J.O.1    Croghan, I.T.2    Severson, H.H.3    Schroeder, D.R.4    Hays, J.T.5
  • 21
    • 84892743698 scopus 로고    scopus 로고
    • A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India
    • Jain R, Jhanjee S, Jain V, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. Nicotine Tob Res. 2014;16:50-57. doi:10.1093/ntr/ntt115.
    • (2014) Nicotine Tob Res , vol.16 , pp. 50-57
    • Jain, R.1    Jhanjee, S.2    Jain, V.3
  • 22
    • 55049140591 scopus 로고    scopus 로고
    • Nicotine receptor partial agonists for smoking cessation
    • Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103. doi:10.1002/14651858.CD006103.pub6.
    • (2012) Cochrane Database Syst Rev , vol.4
    • Cahill, K.1    Stead, L.F.2    Lancaster, T.3
  • 23
    • 84864360423 scopus 로고    scopus 로고
    • Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes
    • Swan GE, Javitz HS, Jack LM, et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J. 2012;12:349-358. doi:10.1038/tpj.2011.19.
    • (2012) Pharmacogenomics J , vol.12 , pp. 349-358
    • Swan, G.E.1    Javitz, H.S.2    Jack, L.M.3
  • 24
    • 84855875894 scopus 로고    scopus 로고
    • Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials
    • King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37:641-650. doi:10.1038/npp.2011.232.
    • (2012) Neuropsychopharmacology , vol.37 , pp. 641-650
    • King, D.P.1    Paciga, S.2    Pickering, E.3
  • 25
    • 33747154992 scopus 로고    scopus 로고
    • Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
    • Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577. doi:10.1001/archinte.166.15.1571.
    • (2006) Arch Intern Med , vol.166 , pp. 1571-1577
    • Oncken, C.1    Gonzales, D.2    Nides, M.3
  • 26
    • 33745611449 scopus 로고    scopus 로고
    • Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    • Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63. doi:10.1001/jama.296.1.56.
    • (2006) JAMA , vol.296 , pp. 56-63
    • Jorenby, D.E.1    Hays, J.T.2    Rigotti, N.A.3
  • 27
    • 33745614361 scopus 로고    scopus 로고
    • Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    • Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55. doi:10.1001/jama.296.1.47.
    • (2006) JAMA , vol.296 , pp. 47-55
    • Gonzales, D.1    Rennard, S.I.2    Nides, M.3
  • 28
    • 64849107623 scopus 로고    scopus 로고
    • Varenicline: a first-line treatment option for smoking cessation
    • Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31:463-491. doi:10.1016/j. clinthera.2009.03.021.
    • (2009) Clin Ther , vol.31 , pp. 463-491
    • Garrison, G.D.1    Dugan, S.E.2
  • 29
    • 62849127996 scopus 로고    scopus 로고
    • Varenicline for smoking cessation: a review of the literature
    • Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: a review of the literature. Curr Ther Res. 2009;70:35-54. doi:10.1016/j. curtheres.2009.02.004.
    • (2009) Curr Ther Res , vol.70 , pp. 35-54
    • Kaur, K.1    Kaushal, S.2    Chopra, S.C.3
  • 30
    • 34547607413 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    • Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29:1027-1039. doi:10.1016/j.clinthera.2007.06.011.
    • (2007) Clin Ther , vol.29 , pp. 1027-1039
    • Tsai, S.T.1    Cho, H.J.2    Cheng, H.S.3
  • 31
    • 33745599140 scopus 로고    scopus 로고
    • Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial
    • Tonstad S, Tønnesen P, Hajek P, etal. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
    • (2006) JAMA , vol.296 , pp. 64-71
    • Tonstad, S.1    Tønnesen, P.2    Hajek, P.3
  • 32
    • 74949122161 scopus 로고    scopus 로고
    • Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
    • Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221-229. doi:10.1161/CIRCULATIONAHA.109.869008.
    • (2010) Circulation , vol.121 , pp. 221-229
    • Rigotti, N.A.1    Pipe, A.L.2    Benowitz, N.L.3    Arteaga, C.4    Garza, D.5    Tonstad, S.6
  • 33
    • 63849201453 scopus 로고    scopus 로고
    • Varenicline for smoking cessation: a placebo-controlled, randomized study
    • Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009;14:384-392. doi:10.1111/j.1440-1843.2008.01476.x.
    • (2009) Respirology , vol.14 , pp. 384-392
    • Wang, C.1    Xiao, D.2    Chan, K.P.W.3    Pothirat, C.4    Garza, D.5    Davies, S.6
  • 34
    • 84876477549 scopus 로고    scopus 로고
    • Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice
    • Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract. 2013;67:469-476. doi:10.1111/ijcp.12121.
    • (2013) Int J Clin Pract , vol.67 , pp. 469-476
    • Wang, C.1    Cho, B.2    Xiao, D.3    Wajsbrot, D.4    Park, P.W.5
  • 35
    • 77955634428 scopus 로고    scopus 로고
    • Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebocontrolled trials conducted in six Asian countries
    • Fagerström K-O, Nakamura M, Cho HJ, et al. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebocontrolled trials conducted in six Asian countries. Curr Med Res Opin. 2010;26:2165-2173. doi:10.1185/03007995.2010.505130.
    • (2010) Curr Med Res Opin , vol.26 , pp. 2165-2173
    • Fagerström, K.-O.1    Nakamura, M.2    Cho, H.J.3
  • 36
    • 67349108044 scopus 로고    scopus 로고
    • Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
    • Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat. 2009;36:428-434. doi:10.1016/j.jsat.2008.09.001.
    • (2009) J Subst Abuse Treat , vol.36 , pp. 428-434
    • Halperin, A.C.1    McAfee, T.A.2    Jack, L.M.3
  • 39
    • 80051599762 scopus 로고    scopus 로고
    • Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand
    • Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf. 2011;34:763-772. doi:10.2165/11594450-000000000-00000.
    • (2011) Drug Saf , vol.34 , pp. 763-772
    • Harrison-Woolrych, M.1    Ashton, J.2
  • 40
    • 84879947696 scopus 로고    scopus 로고
    • Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England
    • Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SAW. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf. 2013;36:521-531. doi:10.1007/s40264-013-0046-6.
    • (2013) Drug Saf , vol.36 , pp. 521-531
    • Buggy, Y.1    Cornelius, V.2    Fogg, C.3    Kasliwal, R.4    Layton, D.5    Shakir, S.A.W.6
  • 41
  • 42
    • 84889028067 scopus 로고    scopus 로고
    • Varenicline, smoking cessation, and neuropsychiatric adverse events
    • Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460-1467.
    • (2013) Am J Psychiatry , vol.170 , pp. 1460-1467
    • Gibbons, R.D.1    Mann, J.J.2
  • 43
    • 84861412607 scopus 로고    scopus 로고
    • Varenicline for Smoking Cessation in Schizophrenia: safety and Effectiveness in a 12-Week Open-Label Trial
    • Pachas GN, Cather C, Pratt SI, et al. Varenicline for Smoking Cessation in Schizophrenia: safety and Effectiveness in a 12-Week Open-Label Trial. J Dual Diagn. 2012;8:117-125. doi:10.1080/15504263.2012.663675.
    • (2012) J Dual Diagn , vol.8 , pp. 117-125
    • Pachas, G.N.1    Cather, C.2    Pratt, S.I.3
  • 44
    • 84884187859 scopus 로고    scopus 로고
    • Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial
    • Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159:390-400. doi:10.7326/0003-4819-159-6-201309170-00005.
    • (2013) Ann Intern Med , vol.159 , pp. 390-400
    • Anthenelli, R.M.1    Morris, C.2    Ramey, T.S.3
  • 45
    • 84891929233 scopus 로고    scopus 로고
    • Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial
    • Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311:145-154. doi:10.1001/jama.2013.285113.
    • (2014) JAMA , vol.311 , pp. 145-154
    • Evins, A.E.1    Cather, C.2    Pratt, S.A.3
  • 46
    • 77949600076 scopus 로고    scopus 로고
    • Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis
    • Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010;33:289-301. doi:10.2165/11319180-000000000-00000.
    • (2010) Drug Saf , vol.33 , pp. 289-301
    • Tonstad, S.1    Davies, S.2    Flammer, M.3    Russ, C.4    Hughes, J.5
  • 47
    • 77953255862 scopus 로고    scopus 로고
    • Varenicline in smoking cessation
    • Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med. 2010;4:291-299. doi:10.1586/ers.10.27.
    • (2010) Expert Rev Respir Med , vol.4 , pp. 291-299
    • Tonstad, S.1    Rollema, H.2
  • 48
    • 84889583200 scopus 로고    scopus 로고
    • Reassessing the safety of varenicline
    • Evins AE. Reassessing the safety of varenicline. Am J Psychiatry. 2013;170:1385-1387.
    • (2013) Am J Psychiatry , vol.170 , pp. 1385-1387
    • Evins, A.E.1
  • 49
    • 84954520636 scopus 로고    scopus 로고
    • Accessed April 29, 2014
    • European Medicines Agency-News and Events-European Medicines Agency Confirms Positive Benefit-Risk Balance for Champix. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001314.jsp&mid=WC0b01ac058004d5c1. Accessed April 29, 2014.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.